A study to evaluate the effect of Dhatryadi Ghrita in Asrigdara/Heavy Menstrual Bleeding

A RANDOMISED OPEN LABELLED CONTROLLED CLINICAL STUDY ON THE EFFICACY OF DHATRYADI GHRITA IN THE MANAGEMENT OF ASRIGDARA WITH SPECIAL REFERENCE TO HEAVY MENSTRUAL BLEEDING - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/105873

Enrollment

Registered

2026-03-10

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N72- Inflammatory disease of cervix uteri

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects between the age group of 18 50 years. 2. Subjects with classical symptoms of Asrigdara -Rakta Atipravritti (Atiprasangen, Deerghakala Raktapravritti (Deerghakalanubandhen), Angamarda. 3. Subjects with non-major Heavy menstrual bleeding. 4. Subjects with current and previous consecutive cycles of heavy menstrual bleeding. 5. Subjects with intermenstrual bleeding in current and previous consecutive cycles. 6. Subjects with regular or irregular periods. 7. Subjects irrespective with marital status and parity. 8. Subjects with Hb percent more than 8gm per dl. Hemodynamically stable. 9. Subjects classified under PALM-COEIN, Dysfunctional Uterine Bleeding (DUB), Abnormal Uterine Bleeding (AUB). 10. Subject with oligomenorrhea with HMB. 11. Subjects with SAMANTA questionnaire score more than 3. 12. Subjects willing to do self-assessment by using Pictorial Blood Assessment Chart (score more than 100.) 13. Subject willing to sign the consent.

Exclusion criteria

Exclusion criteria: 1. Subjects with IUCD and OCP users. 2. Subjects with Pelvic inflammatory diseases. 3. Subject diagnosed with Asrigdara with hemodynamically instability like Moha, Bhrama. 4. Subjects with Hb less than 8g per dl. Major Heavy menstrual bleeding. 5. Local pathology, cervical polyps, cervical erosion, Post menopausal bleeding, Pregnancy, Puerperium, Lactation. 6. Subjects on Anticoagulant treatment. 8. Subjects with other systemic illness like HTN, Diabetes Mellitus, Thyroid, Dyslipidemia, STD s, Prolactinemia. 9. Subjects with coagulopathy and malignancy. (PALM-COEIN)

Design outcomes

Primary

Measure	Time frame
Primary outcomes for the study are to assess decrease in Excessive and prolonged blood loss during menstruationTimepoint: treatment period 2 menstrual cycles. study period 3 menstrual cycles	—

Secondary

Measure	Time frame
Generation of in depth analysed data on the different aspect of the disease. Generation of data on possible unexpected drug reactionTimepoint: treatment period 2 menstrual cycles. study period 3 months	—

Countries

India

Contacts

Public ContactDr Kalyani Prakashrao Chauthe

Sri Sri College of Ayurvedic Science and Research

Shubha.ural@gmail.com9945600058

Outcome results